AVR Key Statistics, Chart & Performance
The current stock price of AVR is 5.22 USD. In the past month the price increased by 5.45%. In the past year, price decreased by -15.81%.
AVR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AVR. When comparing the yearly performance of all stocks, AVR turns out to be only a medium performer in the overall market: it outperformed 64.12% of all stocks.
AVR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AVR. AVR may be in some trouble as it scores bad on both profitability and health.
AVR Financial Highlights
Over the last trailing twelve months AVR reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS decreased by -65.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -440.09% | ||
| ROE | -2269.93% | ||
| Debt/Equity | 0.02 |
AVR Forecast & Estimates
8 analysts have analysed AVR and the average price target is 16.83 USD. This implies a price increase of 222.41% is expected in the next year compared to the current price of 5.22.
For the next year, analysts expect an EPS growth of 22.6% and a revenue growth -38.46% for AVR
AVR Ownership
AVR Latest News, Press Relases and Analysis
AVR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.02 | 188.146B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.95 | 169.625B | ||
| SYK | STRYKER CORP | 23.97 | 137.924B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.17 | 111.924B | ||
| BDX | BECTON DICKINSON AND CO | 13.75 | 59.33B | ||
| IDXX | IDEXX LABORATORIES INC | 43.44 | 51.339B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.38 | 46.291B | ||
| RMD | RESMED INC | 21.75 | 38.394B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.39 | 37.64B | ||
| DXCM | DEXCOM INC | 27.76 | 27.621B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AVR
Company Profile
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 136 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Company Info
ANTERIS TECHNOLOGIES GLOBAL
860 Blue Gentian Road, Suite 340
Eagan MINNESOTA US
Employees: 136
Phone: 16514930606
ANTERIS TECHNOLOGIES GLOBAL / AVR FAQ
What does ANTERIS TECHNOLOGIES GLOBAL do?
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 136 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Can you provide the latest stock price for ANTERIS TECHNOLOGIES GLOBAL?
The current stock price of AVR is 5.22 USD. The price decreased by -6.28% in the last trading session.
Does AVR stock pay dividends?
AVR does not pay a dividend.
What is the ChartMill rating of ANTERIS TECHNOLOGIES GLOBAL stock?
AVR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is ANTERIS TECHNOLOGIES GLOBAL (AVR) expected to grow?
The Revenue of ANTERIS TECHNOLOGIES GLOBAL (AVR) is expected to decline by -38.46% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns ANTERIS TECHNOLOGIES GLOBAL?
You can find the ownership structure of ANTERIS TECHNOLOGIES GLOBAL (AVR) on the Ownership tab.